EU approves Abecma for multiple myeloma – BMS
Bristol Myers Squibb announced that the European Commission has granted Conditional Marketing Authorization for Abecma (idecabtagene vicleucel; ide-cel), a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)… read more.
